{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15(1)"],"submitter":["Sedighiyan M"],"pubmed_abstract":["<h4>Objective</h4>The present study aimed to investigate the effects of nano-curcumin supplementation on adipokines levels and clinical signs in obese and overweight patients with migraine.<h4>Results</h4>Forty-four patients with episodic migraine participated in this clinical trial and were divided into two groups nano-curcumin (80 mg/day) and the control group over 2-month period. At the baseline and the end of the research, the serum levels of MCP-1, Resistin, and Visfatin were measured using the ELISA method. In addition, the headache attack frequencies, severity, and duration of pain were recorded. The results of the present study showed that nano-curcumin can significantly reduce MCP-1 serum levels in the nano-curcumin supplemented group (P = 0.015, size effect = 13.4%). In the case "],"journal":["BMC research notes"],"pagination":["189"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9125853"],"repository":["biostudies-literature"],"pubmed_title":["The effects of nano-curcumin supplementation on adipokines levels in obese and overweight patients with migraine: a double blind clinical trial study."],"pmcid":["PMC9125853"],"pubmed_authors":["Jafari E","Djalali M","Sohrabi Athar S","Sedighiyan M","Abdolahi M","Vahabi Z","Yekaninejad MS","Narimani Zamanabadi M","Hadavi S"],"additional_accession":[]},"is_claimable":false,"name":"The effects of nano-curcumin supplementation on adipokines levels in obese and overweight patients with migraine: a double blind clinical trial study.","description":"<h4>Objective</h4>The present study aimed to investigate the effects of nano-curcumin supplementation on adipokines levels and clinical signs in obese and overweight patients with migraine.<h4>Results</h4>Forty-four patients with episodic migraine participated in this clinical trial and were divided into two groups nano-curcumin (80 mg/day) and the control group over 2-month period. At the baseline and the end of the research, the serum levels of MCP-1, Resistin, and Visfatin were measured using the ELISA method. In addition, the headache attack frequencies, severity, and duration of pain were recorded. The results of the present study showed that nano-curcumin can significantly reduce MCP-1 serum levels in the nano-curcumin supplemented group (P = 0.015, size effect = 13.4%). In the case ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 May","modification":"2025-04-22T03:51:00.635Z","creation":"2025-02-19T01:24:05.431Z"},"accession":"S-EPMC9125853","cross_references":{"pubmed":["35606882"],"doi":["10.1186/s13104-022-06074-4"]}}